CDK4 and cancer: The inhibition of CDK4/6 by palbociclib inhibits the phosphorylation of the retinoblastoma protein (RB), thereby blocking the progression of the cell cycle from the G1 to S phase, which inhibits cancer cell proliferation (Weinberg, 1995; Spring et al., 2020).